Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EPS (Weighted Average and Diluted) (2016 - 2025)

Rockwell Medical's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.01 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 75.0% year-over-year to -$0.01; the TTM value through Dec 2025 reached -$0.15, down 200.0%, while the annual FY2025 figure was -$0.15, 400.0% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.01 in Q4 2025 per RMTI's latest filing, up from -$0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.04 in Q3 2024 to a low of -$1.04 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.3, with a median of -$0.06 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 1055.56% in 2021, then soared 157.14% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.04 in 2021, then soared by 95.19% to -$0.05 in 2022, then increased by 0.0% to -$0.05 in 2023, then rose by 20.0% to -$0.04 in 2024, then surged by 75.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for RMTI's EPS (Weighted Average and Diluted) are -$0.01 (Q4 2025), -$0.05 (Q3 2025), and -$0.05 (Q2 2025).